Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders
• Written informed consent
Locations
Other Locations
Switzerland
Inselspital, University Clinic for Nuclear Medicine
RECRUITING
Bern
Contact Information
Primary
Axel Rominger, Prof. Dr. med.
axel.rominger@insel.ch
+41 316322610
Backup
Franziska Strunz, PhD
studies.nuk@insel.ch
+41 316643022
Time Frame
Start Date: 2024-10-07
Estimated Completion Date: 2026-08-01
Participants
Target number of participants: 20
Treatments
Experimental: NUK-RB Study
Related Therapeutic Areas
Sponsors
Leads: Insel Gruppe AG, University Hospital Bern